For a study, researchers sought to discuss the symptoms, diagnosis, therapy, and prognosis of collecting duct carcinoma (CDC) of the kidney in detail.

They gathered data from 74 CDC patients from two facilities between January 2001 and December 2020. The clinical parameters, imaging, pathology aspects, and diagnostic and therapeutic approaches were all investigated.

The patients’ average age was 61.5 years, and 54.1% were men. Low back discomfort, hematuria, and weariness were the most prevalent complaints. CT scans were inconclusive, with 10.8% of patients diagnosed with urothelial cancer and 4.1% with infectious illness. At the time of presentation, 32 patients had metastases, and 17.6% had tumor thrombus in the venous system. Twenty-two individuals had renal biopsies, and half were diagnosed with CDC. There were 61 renal operations conducted, with a pathological median diameter of 6.5 cm. Immune checkpoint inhibitors were given to eight patients, and the objective remission rate was 50%. The usual duration of follow-up was 16 months, and the median overall survival was 24.0 months. Sarcomatoid differentiation and the lack of renal surgery were found to be predictors of death in both univariate and multivariate analyses.

The CDC is really aggressive. Patients are frequently diagnosed at a late stage. Early surgical intervention can enhance the outcome. Despite the lack of conventional therapy, immune checkpoint inhibitors provide fresh hope for the treatment of CDC.